An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Levemir (Insulin Detemir) in Pregnant Women With Diabetes Mellitus
Latest Information Update: 09 Sep 2024
At a glance
- Drugs Insulin detemir (Primary) ; Insulin glargine; Insulins
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EVOLVE
- Sponsors Novo Nordisk
- 23 Sep 2022 Results (n=2088) of secondary analysis assessing congenital malformations among offspring of women with type 1 diabetes using insulin pump or multiple daily insulin injection presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
- 28 Aug 2022 Results (n=2088) of secondary analysis of the EValuation Of LeVEmir in Pregnancy (EVOLVE) study cohort presented at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
- 30 Jul 2021 Results (n=1,457) assessing risk of severe adverse pregnancy complications in women with preexisting diabetes, published in the Diabetes Care